The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Blueprint Medicines Corp shares valued at $7,713,537 were sold by Durso-Bumpus Debra on Jun 21 ’24. At $104.19 per share, Durso-Bumpus Debra sold 74,034 shares. The insider’s holdings dropped to 43,763 shares worth approximately $4.55 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Carter Percy H. sold 4,000 shares, netting a total of over 420,520 in proceeds. Following the sale of shares at $105.13 each, the insider now holds 41,895 shares.
Before that, Hewes L. Becker had sold 2,424 shares from its account. In a trade valued at $254,302, the CHIEF MEDICAL OFFICER traded Blueprint Medicines Corp shares for $104.91 each. Upon closing the transaction, the insider’s holdings decreased to 2,424 shares, worth approximately $3.07 million.
As published in their initiating research note from Stephens on May 14, 2024, Blueprint Medicines Corp [BPMC] has been an Overweight and the price target has been revised to $140. Analysts at Leerink Partners upgraded the stock from ‘”an Underperform”‘ to ‘”a Market perform”‘ outlook in a report released in early May. As of October 27, 2023, Oppenheimer has increased its “Perform” rating to a “an Outperform” for BPMC. Earlier on August 21, 2023, Needham resumed its rating. Their recommendation was “a Buy” for BPMC stock.
Analyzing BPMC Stock Performance
During the last five days, there has been a drop of approximately -2.61%. Over the course of the year, Blueprint Medicines Corp shares have jumped approximately 12.66%. Shares of the company reached a 52-week high of $111.02 on 05/14/24 and a 52-week low of $72.24 on 02/14/24. A 50-day SMA is recorded $101.76, while a 200-day SMA reached $80.84. Nevertheless, trading volume fell to 0.51 million shares from 0.66 million shares the previous day.
Support And Resistance Levels for Blueprint Medicines Corp (BPMC)
According to the 24-hour chart, there is a support level at 102.84, which, if violated, would cause prices to drop to 101.76. In the upper region, resistance lies at 105.75. The next price resistance is at 107.58. RSI (Relative Strength Index) is 49.36 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.39, which suggests the price will decrease in the coming days. Percent R is at 67.17%, indicating low price movement. Stochastics%K at holding indicates that the stock is to be held.
